Million-Dollar Project Aims to Expose Bad Medical Research
Armed with funding, algorithms, and a tip line, this new effort aims to dig corrupt studies out of medical literature before they do real-world harm.
A new initiative from the watchdogs behind Retraction Watch is taking aim at flawed or faked medical science research to the tune of nearly $1 million.
The Center for Scientific Integrity just launched the Medical Evidence Project, a two-year effort to identify published medical research with a negative effect on health guidelines—and to make sure people actually hear about it.
Equipped with a $900,000 grant from Open Philanthropy and a core team of up to five investigators, the project will use forensic metascience tools to identify issues in scientific articles, and report its findings via Retraction Watch, the foremost site for scientific watchdogging.
'We originally set up the Center for Scientific Integrity as a home for Retraction Watch, but we always hoped we would be able to do more in the research accountability space,' said Ivan Oransky, executive director of the Center and co-founder of Retraction Watch, in a post announcing the grant. 'The Medical Evidence Project allows us to support critical analysis and disseminate the findings.'
According to Nature, these flawed and falsified documents are vexing because they skew meta-analyses—reviews that combine the findings from multiple studies to draw more statistically robust conclusions. If one or two bunk studies make it into a meta-analysis, they can tip the scales on health policy.
In 2009, to name one case, a European guideline recommended the use of beta-blockers during non-cardiac surgery, based on turn-of-the-millennium research that was later called into question. Years later, an independent review suggested that the guidance may have contributed to 10,000 deaths per year in the UK.
Led by James Heathers, a science integrity consultant, the team's plan is to build software tools, chase down leads from anonymous whistleblowers, and pay peer reviewers to check their work. They're aiming to identify at least 10 flawed meta-analyses a year.
The team is picking its moment wisely. As Gizmodo previously reported, AI-generated junk science is flooding the academic digital ecosystem, showing up in everything from conference proceedings to peer-reviewed journals. A study published in Harvard Kennedy School's Misinformation Review found that two-thirds of sampled papers retrieved through Google Scholar contained signs of GPT-generated text—some even in mainstream scientific outlets. About 14.5% of those bogus studies focused on health.
That's particularly alarming because Google Scholar doesn't distinguish between peer-reviewed studies and preprints, student papers, or other less-rigorous work. And once this kind of bycatch gets pulled into meta-analyses or cited by clinicians, it's hard to untangle the consequences. 'If we cannot trust that the research we read is genuine,' one researcher told Gizmodo, 'we risk making decisions based on incorrect information.'
We've already seen how nonsense can slip through. In 2021, Springer Nature retracted over 40 papers from its Arabian Journal of Geosciences—studies so incoherent they read like AI-generated Mad Libs. Just last year, the publisher Frontiers had to pull a paper featuring anatomically impossible AI-generated images of rat genitals.
We've entered the era of digital fossils, in which AI models trained on web-scraped data are beginning to preserve and propagate nonsense phrases as if they were real scientific terms. For example, earlier this year a group of researchers found a garbled set of words from a 1959 biology paper embedded in the outputs of large language models including OpenAI's GPT-4o.
In that climate, the Medical Evidence Project's goal feels more like triage than cleanup. The team is dealing with a deluge of flawed information, hiding in plain sight, and plenty of which can have very real health consequences if taken at face value.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
16 minutes ago
- Yahoo
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an 'Outperform' rating and a $49 price target. The research firm reiterated the company's solid position amid the 'TTR craze' while also echoing its commercial execution strategy. A medical technician wearing a lab coat operating machinery in a biopharmaceutical laboratory. Consequently, Wolfe Research expects BridegBio's revenue to total $569 million in 2025 before rising to $3.4 billion by 2028. It should peak at $4.4 billion in 2034. For the upcoming second quarter, the research firm expects the company to deliver revenue of $106 million, slightly below market expectation of $111 million. While the stock has shown a remarkable return of 42% year to date, Wolfe Research insists it must navigate several challenges to maintain the positive momentum. It must navigate the potential Vyndaqel loss of exclusivity, achondroplasia data versus competition, and pipeline products. In addition, consistent revenue growth and expanding operating margins will be crucial to the company's long-term success. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases. Its pipeline includes a range of development programs, from early science to advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
